Cf1743

Cat. No.: HY-107025 Purity: 99.44%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Cf1743 is a potent anti-varicella-zoster virus (VZV) bicyclic nucleoside analogue. Cf1743 has antiviral activity, with an IC₅₀ of 3.3 μM for VZV thymidine kinase (TK).

For research use only. We do not sell to patients.

Cf1743 Chemical Structure

CAS No. : 319425-66-6

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Cf1743:

CF 1743-d₇ Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cf1743 is a potent anti-varicella-zoster virus (VZV) bicyclic nucleoside analogue. Cf1743 has antiviral activity, with an IC₅₀ of 3.3 μM for VZV thymidine kinase (TK)^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
HEL	CC₅₀	> 200 μM Compound: 3	Cytotoxicity against human HEL cells Cytotoxicity against human HEL cells	[PMID: 19328697]
HEL	CC₅₀	> 200 μM Compound: 4f	cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus	[PMID: 11150169]
HEL	CC₅₀	> 200 μM Compound: f	Cytotoxic activity against cultured human embryonic lung (HEL) cells Cytotoxic activity against cultured human embryonic lung (HEL) cells	[PMID: 16392824]
HEL	CC₅₀	> 50 μM Compound: 1, BCNA	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 18052321]
HEL	CC₅₀	> 50 μM Compound: 4	Cytotoxicity against HEL cells after 3 days Cytotoxicity against HEL cells after 3 days	[PMID: 17622128]
HEL	CC₅₀	>= 100 μM Compound: 1, Cf1743	Cytotoxicity against HEL cells assessed as inhibition of cell proliferation Cytotoxicity against HEL cells assessed as inhibition of cell proliferation	[PMID: 21332170]
HEL	EC₅₀	0.0001 μM Compound: 1, BCNA	Antiviral activity against TK+ VZV YS in HEL cells after 5 days Antiviral activity against TK+ VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.0001 μM Compound: 4f	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.0003 μM Compound: 1, BCNA	Antiviral activity against TK+ VZV OKA in HEL cells after 5 days Antiviral activity against TK+ VZV OKA in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	0.0003 μM Compound: 4f	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	0.0005 μM Compound: 3	Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella Zoster virus YS infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19328697]
HEL	EC₅₀	0.0006 μM Compound: 3	Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella Zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19328697]
HEL	EC₅₀	0.001 μM Compound: 4	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	0.003 μM Compound: 1, Cf1743	Antiviral activity against Varicella zoster virus OKA infected in HEL cells assessed as reduction in virus induced cytopathicity Antiviral activity against Varicella zoster virus OKA infected in HEL cells assessed as reduction in virus induced cytopathicity	[PMID: 21332170]
HEL	EC₅₀	0.004 μM Compound: 1, Cf1743	Antiviral activity against Varicella zoster virus YS infected in HEL cells assessed as reduction in virus induced cytopathicity Antiviral activity against Varicella zoster virus YS infected in HEL cells assessed as reduction in virus induced cytopathicity	[PMID: 21332170]
HEL	EC₅₀	0.004 μM Compound: 4	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	0.0097 μM Compound: 1, BCNA	Antiviral activity against Varicella zoster virus OKA infected human HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against Varicella zoster virus OKA infected human HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19833513]
HEL	EC₅₀	> 0.5 μM Compound: 4	Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	> 1.3 μM Compound: 4	Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	> 10 μM Compound: 4	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	EC₅₀	> 10 μM Compound: 4	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	EC₅₀	> 20 μM Compound: 1, BCNA	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected human HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected human HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 19833513]
HEL	EC₅₀	> 20 μM Compound: 12, BCNA	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	> 20 μM Compound: 12, BCNA	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	> 20 μM Compound: 12, BCNA	Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	> 20 μM Compound: 4f	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	> 5 μM Compound: 1, BCNA	Antiviral activity against TK- VZV 07 in HEL cells after 5 days Antiviral activity against TK- VZV 07 in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	> 5 μM Compound: 1, BCNA	Antiviral activity against TK- VZV YS in HEL cells after 5 days Antiviral activity against TK- VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	> 5 μM Compound: 4f	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HeLa	CC₅₀	> 200 μM Compound: 2	Cytotoxic concentration required to inhibit Hel cell growth Cytotoxic concentration required to inhibit Hel cell growth	[PMID: 15109620]
HeLa	CC₅₀	> 200 μM Compound: 4	Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent	[PMID: 15993062]

Molecular Weight

398.45

Formula

C₂₂H₂₆N₂O₅

CAS No.

319425-66-6

Appearance

Solid

Color

White to off-white

SMILES

O=C1N=C2C(C=C(C3=CC=C(C=C3)CCCCC)O2)=CN1[C@@H](C[C@@H]4O)O[C@@H]4CO

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Purity: 99.44%

Select Batch:

Data Sheet (265 KB) SDS (252 KB)

COA (245 KB) HNMR (188 KB) NP-HPLC (362 KB) LCMS (121 KB)

Handling Instructions (2659 KB)

References

[1]. McGuigan C, et al. 2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus bicyclic nucleoside analogue (BCNA) Cf 1743. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6264-7. [Content Brief]

Cf1743 Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cf1743319425-66-6Cf 1743Cf-1743Nucleoside Antimetabolite/Analogvaricella-zoster virusVZVTKVZVantiviralbicyclic nucleoside analogueInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *